Summary
Quest Diagnostics Incorporated (DGX) announced in an 8-K filing dated March 2, 2018, that its CEO, Stephen H. Rusckowski, and CFO, Mark J. Guinan, have each adopted Rule 10b5-1 trading plans. These plans allow them to sell shares of company stock acquired through the exercise of vested stock options. The plans are designed to facilitate diversification of their personal investment portfolios and were established at a time when they were not in possession of material non-public information regarding the company. Specifically, Mr. Rusckowski's plan permits the sale of up to 168,490 shares underlying vested stock options, and Mr. Guinan's plan allows for the sale of up to 61,533 shares. Both plans have termination dates on or around September 21, 2018, or upon the sale of all shares covered by the plan. These disclosures are standard for executive stock transactions and are intended to provide transparency to investors.
Key Highlights
- 1CEO Stephen H. Rusckowski adopted a Rule 10b5-1 trading plan to sell up to 168,490 shares from vested stock options.
- 2CFO Mark J. Guinan adopted a Rule 10b5-1 trading plan to sell up to 61,533 shares from vested stock options.
- 3These trading plans were established on February 20, 2018 (CEO) and February 22, 2018 (CFO).
- 4The plans are intended for personal investment portfolio diversification and were entered into when executives were not in possession of material non-public information.
- 5Transactions under these plans will be publicly disclosed via SEC filings.
- 6Both plans are set to terminate on or before September 21, 2018, or when all planned shares are sold.
- 7This filing is a Regulation FD disclosure.